




Cerebrospinal Fluid Folate 
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A young woman with Kearns-Sayre syndrome and 
progressive central nervous system deterioration over 15 
years had decreased plasma and cerebrospinal fluid 
folate levels while receiving phenytoin for a seizure 
disorder. A muscle biopsy showed a “ragged red fiber” 
myopathy with reduced muscle carnitine and mito- 
chondrial enzymes. Computed tomographic brain scans 
showed cerebral white matter hypodensities and bi- 
lateral calcification of the basal ganglia. The mechanism 
for the folate deficiency and altered ratio of plasma to 
cerebrospinal fluid folate is unknown, but the deficiency 
may be responsive to replacement therapy. 
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Kearns-Sayre syndrome (KSS) is a multisystem disor- 
der occurring in childhood. It is characterized by the 
triad of progressive external ophthalmoparesis, con- 
duction heart block, and atypical pigmentary degenera- 
tion of the retina, and can be distinguished from other 
forms of “ophthalmoplegia plus” r2, 11, 161. An ac- 
companying encephalopathy originally observed post- 
mortem may now be identified in computed tomo- 
graphic (CT) brain scans as calcification of the basal 
ganglia or white matter hypodensities [S, 21, 261. Mus- 
cle biopsies show ragged red fibers suggesting a mito- 
chondrial disorder { 31. Endocrinopathies, particularly 
hypoparathyroidism, have also been observed in some 
patients with KSS [15J The neurological symptoms of 
KSS resemble the syndrome of folate malabsorption 
1171. We describe a patient with KSS who was found to 
have reduced plasma and cerebrospinal fluid (CSF) fo- 
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late levels without evidence of malabsorption. The pa- 
tient improved after receiving oral folates, D, L-carni- 
tine, and methionine C91. 
Case Report 
K.A. was born at 32 weeks’ gestation and weighed 2.1 kg. 
Following six weeks of incubator care, her growth and devel- 
opment were normal until age 9,  when generalized absence 
and tonic-clonic seizures appeared and were treated with 
phenytoin and phenobarbital. Over the next 11  years, her 
schoolwork, memory, behavior, coordination, strength, and 
gait deteriorated. External ophthalmoparesis with bilateral 
pigmentary degeneration of the retina and bilateral ptosis was 
first observed at age 12, as was proximal muscle weakness. A 
serum calcium of 5.0 mEq/L and an Ellsworth-Howard test 
suggested primary hypoparathyroidism. Thyroid and adrenal 
function tests were normal but a glucose tolerance test sug- 
gested mild chemical diabetes. Electroencephalograms were 
diffusely slow with frequent, generalized, high-voltage 2 to 3 
cps spike-wave discharges. The CSF showed 27 mononuclear 
cells per milliliter and a protein of I74 mgidl. CSF glucose, 
cultures, and the colloidal gold curve were normal. Intrave- 
nous in jection of edrophonium chloride (Tensilon) produced 
no effect. The patient was subsequently treated with pheny- 
toin, phenobarbital, acetazolamide, vitamin D (10,000 units), 
and an antacid (Amphojel). 
At age 17, the patient’s electrocardiogram showed left axis 
deviation of - 20”. IQ was 68 on the Wechsler Adult Intelli- 
gence Scale. The first muscle biopsy showed ragged red 
fibers, but serum creatine kinase levels were normal. Bilateral 
basal ganglion calcifications and white matter hypodensities 
were observed in CT brain scan. At age 2 1 the patient had an 
episode of unexplained coma. Physical examination was 
otherwise unchanged. All serum chemical analyses were nor- 
mal except potassium (2.2 mEq/L), calcium (13.2 mgidl), and 
amylase of 385 units, which had decreased to 120 units upon 
discharge from the hospital. The hematocrit was 2 4 p  and the 
bone marrow was hypocellular but without megaloblastic 
changes. Serum cobalamin (vitamin B12) and iron levels were 
normal. Serum calcium had decreased to 7.6 mddl at dis- 
charge. The patient recovered after several days of hydration 
and antibiotics. Phenobarbital was discontinued and pheny- 
toin and vitamin D therapy maintained. 
By 23 years of age the patient was bedridden and de- 
creased plasma and CSF folate levels were found (Table 1) 
[23]. Phenytoin was discontinued. A second muscle biopsy 
showed a low free carnitine (Table 2); esterified carnitine 
fractions were also similarly decreased although the plasma 
carnitine was normal (57 and 38 nmoVml; mean of 59 con- 
trols * standard deviation, 51.07 * 11.07; range, 35.0- 
69.8). The urine nitroprusside test (Brand Test) for sulfur- 
containing amino acids was negative. Treatment was initiated 
with folk acid, D, L-carnitine, and methionine. A third, post- 
treatment needle biopsy indicated a slight increase in free 
carnitine from 2.7 nmoVmg noncollagen protein to 6.94 
nmollmg. During the following year the patient began to 
walk with the aid of a walker. When she was 25 years of age, a 
persistent cardiac conduction defect necessitated pacemaker 
implantation. 
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Table 1.  Plasma and CSF Folate Level3 in  Patient 
at Age 23 and in  Control Subjects 
Plasma Folate CSF Folate PlasmaiCSF 










1.9 1.1 1.7 
1 .o 1.0 1.0 
28.0 11.0 2.5 
4.5-12.9 3-4 times <1.0 
8.24 & 0.43b plasma 
folate 
levels 
"Values are expressed as range from 20 normal control subjects [23] .  
bMean 2 standard error of the mean. 
Methods and Results 
Written informed consent was obtained for folate studies 
when the patient was age 23. During hospitalization hemo- 
globin, hematocrit, mean corpuscular volume, and serum 
cobalamin levels were normal. Five, lo-methylenetetra- 
hydrofolate reductase (5,lO-MTHFR) activity was normal in 
leukocytes (study performed by Dr  P. Wong, Rush Presbyte- 
rian-St. Lukes Hospital, Chicago [31]). A 24-hour urine for- 
miminoglutamate excretion following oral administration of 
100 mglkg of histidine was normal (10.8 mg) [14]. Plasma 
amino acids were normal with methionine ranging from 11.4 
to 57.8 FmolIL (normal range, 6-39 FmoliL) and a CSF 
methionine of 2.8 FmoliL (normal range, 2.6-3.0 FmoliL) 
[25]. Folate tissue stores were saturated with 5 mg per day of 
folic acid intramuscularly for three days before the oral folate 
absorption study. Then, following an oral dose of 40 Fg of 
folic acid per kilogram of body weight (a total of 1.45 mg, as 
folvite), folate levels increased to normal; from fasting the 
values at 30, 60, 90, and 120 minutes were 37, 74, 70, 59, 
and 47 nglml, respectively [6}. The fasting CSF folate was 17 
nglml with a persistently increased ratio of plasma to CSF 
folate of 2.2. Pretreatment plasma and CSF folate levels were 
low, and although plasma levels appeared to respond to oral 
folate treatment the ratio of plasma to CSF folate remained 
high (see Table 1). Replacement therapy included 15 mg per 
day of folic acid, 500 mg per day of methionine, and 10 g per 
day of D, L-carnitine. The carnitine was reduced to 2 gm per 
day when gastrointestinal intolerance appeared. Supplemen- 
tal oral leucovorin (6 mg per day) was given for the first two 
months in addition to folic acid. 
Discussion 
Abnormally low folate levels have been observed in 
senile dementias, convulsive disorders, neuropathies, 
and hypotonia in infants, conditions often without 
specific causes [20, 22, 27). Classical homocystinuria 
(cystathionine synthase deficiency) may also be accom- 
panied by reduced plasma folate [ S ] .  Homocystinuria 
due to deficient 5,lO-MTHFR has recently been asso- 
ciated with a reversed ratio of CSF to plasma folate and 
reduced muscle carnitine, as well as clinical evidence of 
a leukoencephalopathy and lipid storage myopathy [l}. 
Congenital folate malabsorption, a syndrome associ- 
ated with ataxia, hypotonia, and mental retardation, is 
also accompanied by megaloblastosis, which was not 
found in this patient. Undernutrition and phenytoin 
therapy (which can also cause ophthalmoparesis) re- 
portedly reduce plasma and CSF folates C18, 19, 29). 
Severe neurological disability resulting primarily from 
low folates alone, however, is a disputed occurrence 
This patient had all the features of KSS, along with 
decreased muscle carnitine and mitochondrial en- 
zymes. Studies excluded folate malabsorption and in- 
born errors of folate metabolism [12). Although mal- 
nutrition and even phenytoin may have some effect on 
plasma folate, a defect in the distribution of folates is 
evident in this patient by the persistently low CSF fo- 
late levels. Folate deficiency has been associated with 
altered CSF amine metabolites and neuropsychiatric 
disorders, but the precise cause of the encephalopathy 
cm 
Table 2. Mitochondria1 Enzymes and Carnitine Concentration in  Muscle of Patient at Age 23 and in  Control Subjects 
Control Subjects" 
Patient (n = 59)  
Patient Compared to 
Control Subjects (57) 
Cytochrome C oxidaseb 0.27 2.38 ? 0.44 (22) 
Citrate synthetaseb 1.25 7.88 & 2.52 (12) 
Carnitine acetyItransferaseb 1.45 1.57 & 0.48 (21) 
Carnitine palmityltransferase' 0.60 7.45 2 1.44 (58) 
Free carnitineJ 2.70 19.33 & 1 .77  (68) 







"Values are expressed as mean 2 standard deviation. 
b~mol imidgm fresh tissue. 
'nmol carnitine exchangedmidgm fresh tissue. 
'nmolimg noncollagen prorein. 
Numbers in parentheses indicate number of control subjects 
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in KSS is unknown C41. There was a prompt plasma 
folate response in this patient but the CSF folate was 
not significantly affected by treatment and the ratio of 
plasma to CSF folate did not approach normal [13]. 
Theoretical possibilities include an altered energy- 
dependent transport system or the excessive binding of 
folates by proteins in the choroid plexus. A specific 
primary defect was not apparent in this patient, how- 
ever [7,  28, 301. Three other patients in our clinic with 
calcification of the basal ganglia without the clinical 
triad of KSS had normal plasma and CSF folate levels 
(unpublished data, 1782). 
The decreased activity of several mitochondria en- 
zymes in the muscle biopsy of this patient is probably 
the nonspecific consequence of an unknown alteration 
of the mitochondria (241. Low carnitine palmitoyltrans- 
ferase activity has not previously been reported as a 
secondary phenomenon. One may speculate that there 
is a basic disorder of mitochondrial enzyme function of 
unknown cause in KSS which may be influenced by 
pharmacological amounts of prerins such as folic acid, 
as well as the related substrates methionine and car- 
nitine [lo}. Because a specific mechanism for the 
increased ratio of plasma to CSF folate in KSS is 
unknown, however, this abnormality may be an 
epiphenomenon with an associated nonspecific thera- 
peutic response. Clinical improvement was evident, 
and there was an increase in muscle free carnitine, al- 
though this change may not be important. Additional 
studies are necessary in patients with KSS, to deter- 
mine the frequency of abnormalities in the ratio of CSF 
to plasma folate and to identify a possible pathogenic 
mechanism. 
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Evidence that Lack of 
Deoxyribonucleic Acid 
Repair Causes Death of 
Neurons in Xeroderma 
Pigmentosum 
Jay H. Robbins, MD,* Ronald J. Polinsky, MD,? 
and Alan N. Moshell, MD"J 
Xeroderma pigmentosum (XP) is an autosomal recessive 
disorder with hypersensitivity to the lethal effects of 
ultraviolet radiation caused by inherited defects in 
deoxyribonucleic acid (DNA) repair processes. Some 
patients with XP develop a primary neuronal de- 
generation which has been thought to result from un- 
repaired damage in neuronal DNA. Five years ago we 
reported that cultured skin fibroblasts from a 12-year- 
old girl with XP, who then had only one major neuro- 
logical abnormality of the disease, had a sensitivity 
to ultraviolet radiation intermediate between that of XP 
patients with numerous neurological abnormalities and 
those with none. Recent neurological studies reveal that 
she has a slowly but progressively developing sensori- 
neural deafness as well as cerebellar and motor dysfunc- 
tion typical of XP. The results support the postulate that 
defective DNA repair is associated with premature 
neuron death. 
Robbins JH, Polinsky RJ, Moshell AN: Evidence 
that lack of deoxyribonucleic acid repair causes 
death of neurons in xeroderma pigmentosum. 
Ann Neurol 13:682-684, 1983 
Xeroderma pigmentosum (XP) is an autosomal reces- 
sive disease characterized by accelerated actinic damage 
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F i g  I .  Relationship between neurological abnormalities of pa- 
tients with X P  and the post-UV colony-fomzing ability of their 
jibroblasts. Explanation and discussion are in text. This figure is 
based substantially on Figure 2 of ref 13 but with the nomzal do- 
nor zone mod$ed in accord with 4 3 .  
to skin and other sun-exposed tissues 1151. Some 
patients with XP also have a primary neuronal de- 
generation [15). The major neurological features of 
XP include microcephaly, progressive mental deterio- 
ration, choreoathetosis, ataxia, sensorineural deafness, 
areflexia, extensor plantar responses, spasticity, and a 
neuropathic electromyograph and muscle biopsy [ 151. 
Loss of neurons is prominent in the pyramidal cells of 
the cortex, the Purkinje cells of the cerebellum, the 
deep nuclei of the basal ganglia and cerebellum, the 
zona compacta of the substantia nigra, and the locus 
ceruleus [l5,  17). In advanced cases the spinal cord 
pathology resembles that observed in cases of Fried- 
reich ataxia [17). The constellation of most of these 
findings with retarded growth and sexual development 
has been referred to as the De Sanctis-Cacchione syn- 
drome [ 5 ,  151. 
Cells from patients with XP show abnormal repair of 
DNA when damaged by ultraviolet (UV) radiation or 
certain UV-mimetic chemicals 16, 15). There are cur- 
rently eight known genetic forms of XP: the variant 
form, which has abnormal postreplication repair but a 
normal rate of UV-induced unscheduled DNA repair 
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